GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Kraig Biocraft Laboratories Inc (OTCPK:KBLB) » Definitions » Debt-to-EBITDA

Kraig Biocraft Laboratories (Kraig Biocraft Laboratories) Debt-to-EBITDA : -0.37 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Kraig Biocraft Laboratories Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kraig Biocraft Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.69 Mil. Kraig Biocraft Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.05 Mil. Kraig Biocraft Laboratories's annualized EBITDA for the quarter that ended in Dec. 2023 was $-4.76 Mil. Kraig Biocraft Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.37.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Kraig Biocraft Laboratories's Debt-to-EBITDA or its related term are showing as below:

KBLB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.69   Med: -0.44   Max: -0.02
Current: -0.69

During the past 13 years, the highest Debt-to-EBITDA Ratio of Kraig Biocraft Laboratories was -0.02. The lowest was -0.69. And the median was -0.44.

KBLB's Debt-to-EBITDA is ranked worse than
100% of 1213 companies
in the Chemicals industry
Industry Median: 2.28 vs KBLB: -0.69

Kraig Biocraft Laboratories Debt-to-EBITDA Historical Data

The historical data trend for Kraig Biocraft Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kraig Biocraft Laboratories Debt-to-EBITDA Chart

Kraig Biocraft Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.53 -0.52 -0.33 -0.55 -0.69

Kraig Biocraft Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -0.99 -0.93 -1.06 -0.37

Competitive Comparison of Kraig Biocraft Laboratories's Debt-to-EBITDA

For the Specialty Chemicals subindustry, Kraig Biocraft Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kraig Biocraft Laboratories's Debt-to-EBITDA Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Kraig Biocraft Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kraig Biocraft Laboratories's Debt-to-EBITDA falls into.



Kraig Biocraft Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kraig Biocraft Laboratories's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.694 + 0.054) / -2.518
=-0.69

Kraig Biocraft Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.694 + 0.054) / -4.764
=-0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Kraig Biocraft Laboratories  (OTCPK:KBLB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Kraig Biocraft Laboratories Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Kraig Biocraft Laboratories's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Kraig Biocraft Laboratories (Kraig Biocraft Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
2723 South State Street, Suite 150, Ann Arbor, MI, USA, 48104
Kraig Biocraft Laboratories Inc is engaged in the development of high-strength fibers using recombinant DNA technology mainly for commercial applications. It uses genetic engineering technologies to develop fibers with greater strength, resiliency, and flexibility for use in its target markets, namely the textile, specialty fiber, and technical textile industries. Its products include Monster Silk, which incorporates the natural elasticity of spider silk to make a silk fiber that is more flexible than conventional silk fibers and textiles; and Dragon Silk, which combines the elasticity of Monster Silk with additional high strength elements of native spider silk; Spydasilk; and Spydra. It generates the majority of its revenues from its business across the United States.
Executives
Jonathan Richard Rice officer: COO 2723 S STATE STREET, SUITE 150, ANN ARBOR MI 48104
Kimberly Kraig Thompson director, 10 percent owner, officer: CEO, CFO 2723 S STATE STREET, SUITE 150, ANN ARBOR MI 48401

Kraig Biocraft Laboratories (Kraig Biocraft Laboratories) Headlines

From GuruFocus

Kraig Biocraft Laboratories Receives $1.5 Million in Capital Funding

By GuruFocusNews GuruFocusNews 04-14-2022